Source Mutiple Sclerosis News Today: In the future, a blood test may make diagnosing multiple sclerosis (MS) much easier, thanks to newly identified biomarker patterns that distinguish between MS patients and healthy people.
Diagnostic Blood Test May Be Able to Distinguish Between RRMS and PPMS, Researchers Say Read More »
Source MS Society: A new oral treatment for relapsing MS, called cladribine, will be made available on the NHS in England and Wales within the next three months.
Cladribine: new oral treatment to be available for people with relapsing MS Read More »
Source Multiple Sclerosis News Today: A blood-clotting protein called fibrinogen prevents myelin production and blocks the neuron remyelination repair process in mice, a study finds.
Source MS Society: Researchers in the US have proclaimed their initial test of ibudilast for MS a success.
Positive results for clinical trial in progressive MS Read More »
Source Labiotech.eu BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to study the genetics of multiple sclerosis and accelerate research.
Swiss Genomics Firm, Biogen and Microsoft Team Up to Treat Multiple Sclerosis Read More »
Source Tech Crunch: When there’s a problem in the brain, it pays to be precise — every millimeter counts with something like a tumor or blocked artery.
3D printing brain scans helps doctors with a tricky diagnosis Read More »
Source Multiple Sclerosis News Today: A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease. Importantly, most patients required only the standard two-phase treatment course. Few needed additional courses because of relapse or new brain lesions. Read on.
Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study Read More »
Source MS Society: A new study will investigate whether early treatment with aggressive disease modifying therapies (DMTs) could benefit people with MS.
New study to look at impact of early treatment with aggressive DMTs Read More »
Source Multiple Sclerosis News Today: Disarm Therapeutics has completed the first round of financing to develop a compound that prevents axonal degeneration in patients with multiple sclerosis (MS) and other neurodegenerative conditions.
Disarm Therapeutics to Begin Developing Therapy that Prevents Axonal Degeneration Read More »
Research Talk Date: Monday 13th November 2017, Time: 10:30 – 13:30 Venue: The Salvation Army Hall Chalfont Close, Lower Earley, RG6 5HZ
MS Society Research Talk 13th November Read More »
